BenRalizumab Effect on Airway Remodeling in Severe asTHma

NCT06288516 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Asthma; Eosinophilic
Airway Remodeling

Interventions

DRUG: Benralizumab 30 mg/ml

Sponsor

Aristotle University Of Thessaloniki

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]